

Effectiveness of Chlorhexidine Bathing to Reduce Catheter-Associated Bloodstream Infections in Medical Intensive Care Unit Patients

Susan C. Bleasdale, MD; William E. Trick, MD; Ines M. Gonzalez, MD; Rosie D. Lyles, MD; Mary K. Hayden, MD; Robert A. Weinstein, MD

Objective: To determine whether patients bathed daily with chlorhexidine gluconate (CHG) have a lower incidence of primary bloodstream infections (BSIs) compared with patients bathed with soap and water.

Methods: The study design was a 52-week, 2-arm, crossover (ie, concurrent control group) clinical trial with intention-to-treat analysis. The study setting was the 22-bed medical intensive care unit (MICU), which comprises 2 geographically separate, similar 11-bed units, of the John H. Stroger Jr (Cook County) Hospital, a 464-bed public teaching hospital in Chicago, Illinois. The study population comprised 836 MICU patients. During the first of 2 study periods (28 weeks), 1 hospital unit was randomly selected to serve as the intervention unit in which patients were bathed daily with 2% CHG-impregnated washcloths (Sage 2% CHG cloths; Sage Products Inc, Cary, Illinois); patients in the concurrent control unit were bathed daily with soap and water. After a 2-week wash-out period at the end of the first period, cleansing methods were crossed over for 24 more weeks. Main out-

come measures included incidences of primary BSIs and clinical (culture-negative) sepsis (primary outcomes) and incidences of other infections (secondary outcomes).

Results: Patients in the CHG intervention arm were significantly less likely to acquire a primary BSI (4.1 vs 10.4 infections per 1000 patient days; incidence difference, 6.3 [95% confidence interval, 1.2-11.0]). The incidences of other infections, including clinical sepsis, were similar between the units. Protection against primary BSI by CHG cleansing was apparent after 5 or more days in the MICU.

Conclusions: Daily cleansing of MICU patients with CHG-impregnated cloths is a simple, effective strategy to decrease the rate of primary BSIs.

Trial Registration: clinicaltrials.gov Identifier: NCT00130221

Arch Intern Med. 2007;167(19):2073-2079

EACH YEAR, AN ESTIMATED 80 000 patients in US intensive care units (ICUs) incur catheter-associated bloodstream infections (BSIs). Because of the impact on patient outcomes and since many of these infections are preventable, reduction in BSI risk is the focus of several recent or ongoing patient safety initiatives.¹⁻⁵

Most catheter-associated BSIs result from contamination of the catheter by bacteria residing on patients' skin at the time of device insertion, later from microorganisms migrating from the skin to catheter tip,⁶ or after catheter hub contamination, often also by patients' own skin flora. The risk of BSI is reduced by antiseptic skin preparation immediately before catheter insertion and by keeping microbial density at the insertion site low while the catheter is in place.^{6,7} Chlorhexidine gluconate (CHG), which has broad antimicrobial activity, pro-

longed residual effect, and superiority over iodophor skin preparations, is the recommended agent for disinfecting skin before catheter insertion.⁷⁻¹⁰

See also page 2066

Because catheter-associated BSI is usually caused by patients' resident skin flora, decolonization of a larger area of skin has biological plausibility for reducing catheter-associated infection rates. In a previous study with historical controls,¹¹ we found that compared with soap and water bathing, daily bathing with CHG reduced microbial density on patients' skin, incidence of vancomycin-resistant enterococcal colonization, and BSI rates.^{1,12} In the present study, we report a new clinical trial using concurrent controls and a crossover design to test whether CHG cleansing would decrease the incidence of primary BSIs compared with soap and water baths.

Author Affiliations: Departments of Medicine (Infectious Diseases) (Drs Bleasdale, Gonzales, Hayden, and Weinstein), and Pathology (Dr Hayden), Rush University Medical Center, and Department of Medicine (Collaborative Research Unit) (Dr Trick) and Department of Medicine (Infectious Diseases) (Drs Bleasdale, Gonzalez, Lyles, and Weinstein), Cook County Bureau of Health Services, Chicago, Illinois.




Figure 1. The crossover design. During the first 28-week period, medical intensive care unit (MICU) A was randomly assigned as the intervention unit in which patients were bathed daily with 2% chlorhexidine gluconate-impregnated cloths (Sage Products Inc, Cary, Illinois). Patients in the concurrent control unit were bathed daily with soap and water. This period was followed by a 2-week “washout” period during which patients were bathed with soap and water in both units. We then crossed over the patient cleansing procedures during the second 24-week period.

METHODS

DESIGN OVERVIEW

This was a prospective, 2-arm, crossover (ie, concurrent control group) clinical trial of daily bathing with no-rinse, 2% CHG-impregnated washcloths (Sage 2% chlorhexidine gluconate cloths; Sage Products Inc, Cary, Illinois) vs soap and water bathing. The main study outcomes were primary BSI and clinical (culture-negative) sepsis¹³; the secondary study outcome was the occurrence of other nosocomial infections. The institutional review board waived the need for informed consent.

SETTING AND PARTICIPANTS

We studied the medical ICU (MICU) at John H. Stroger Jr (Cook County) Hospital, a 464-bed public teaching hospital in Chicago, Illinois. The 22-bed MICU comprises 2 geographically separate, similar 11-bed units. Each unit has a dedicated nursing staff; 1 team of attending and resident physicians cares for patients in both units. The MICU catheter insertion policy mandated sterile technique, full barrier drapes, and insertion site disinfection with 2% CHG; antiseptic- or antibiotic-coated catheters were not used. No other catheter-associated BSI infection control interventions were implemented during the study.

We calculated a sample size to detect a 75% reduction of primary BSI risk, a reduction consistent with results of our earlier study.¹² Using previously collected data, we estimated MICU census of 235 patient-days per unit per month and a primary BSI rate of 12 per 1000 patient-days. Setting the α level at .05 and power at 80%, we calculated a prespecified study duration of 12 months.

INTERVENTION

Crossover

We divided the study into 2 periods. During the first, June 8 through December 20, 2005 (28 weeks), we randomly selected one unit (MICU A) to serve as the intervention unit where patients were bathed daily with 2% CHG-impregnated washcloths (Sage); this was designated the CHG arm. Patients in the concurrent control unit were bathed daily with soap and water (soap and water arm). The first period was followed by a 2-week “washout” period during which patients were bathed with soap and water in both units. We then crossed over pa-

tient cleansing procedures during the second period, January 5 through June 21, 2006 (24 weeks) (**Figure 1**). We studied parallel units rather than randomly assigning the intervention at the patient level because a unit-level intervention likely would be more generalizable to use patterns outside of a study setting, and the effect at the group level may reduce risk of intra-unit spread of pathogens between patients.

Bathing Procedure

Nurses were instructed on the standardized bathing procedure relevant to their unit as described previously,¹¹ with the following modifications. For CHG baths, 8 cloths, rather than 6, were used to clean patients' bodies up to the jawline, and 2 nonmedicated cloths were used to clean patients' faces. For patient comfort, packaged cloths were placed in a dedicated warmer (51.7°C) before use. For soap and water baths, nurses used warm water in a disposable basin and bar soap (Pure & Natural; Dial Corp, Scottsdale, Arizona) applied with 10 fresh terry cloth washcloths per bath. We monitored nurses' bathing technique in both arms episodically.

All patients were bathed using the unit's designated procedure with the following exceptions. Patients in the CHG arm with greater than 20% body surface area disruption of skin integrity, who declined participation or who developed a rash that might be attributed to CHG, were bathed with soap and water.

Data Collection

For all patients, we recorded age, sex, invasive device use (ie, intravascular devices, urinary bladder catheters, mechanical ventilation, and feeding tubes), daily temperature, decubitus ulcers, hemodialysis, vasopressor and antibiotic receipt, APACHE II (Acute Physiology and Chronic Health Evaluation II) score, immunosuppressive conditions (human immunodeficiency virus, diabetes, neutropenia, leukemia, and lymphoma), and in-unit mortality.

For infection surveillance, daily electronic review¹⁴ of microbiological cultures and new orders for antibiotic therapy were obtained for participants who were present in the MICU for more than 48 hours. To determine whether a patient had an infection related to MICU stay, we performed a medical record review whenever a positive clinical culture was detected or a new order for antibiotic therapy was given. Clinical and laboratory data were entered on standardized forms and evaluated independently by 3 physician investigators (S.B., I.G., and R.W.). The initial 2 reviewers (S.B. and I.G.) were unblinded to intervention assignment; the third reviewer (R.W.) was blinded. Discrepant interpretations were adjudicated by discussion and consensus among the 3 reviewers; if uncertainties persisted, a fourth physician investigator (W.T.), also blinded to intervention assignment, was consulted. To evaluate whether reviews were biased, we also calculated BSI rates using a computer algorithm on a data warehouse.¹⁵ Agreement between investigator reviews and computer algorithm determinations was high ($\kappa=0.74$), the same as observed in a previous study.¹⁵ Also, there was no difference in level of agreement between arms ($P=.82$), suggesting that misclassification bias during BSI determination was rare or nonexistent.

Events prompting medical record review were categorized as noninfectious, infection related to MICU stay, or infection present or incubating before MICU admission. Using Centers for Disease Control and Prevention definitions,¹³ we classified infections that were determined to be related to MICU stay as primary BSI (intravascular catheter-associated, laboratory-confirmed BSI), clinical (culture-negative) sepsis (fever with no apparent infectious source that was treated with antibiotics), secondary BSI (related to another clinical site), ventilator-associated pneumonia, pneumonia, urinary tract infection, *Clos-*

tridium difficile-associated diarrhea, or other infection. Contaminated blood cultures were defined as episodes in which a common skin commensal (eg, coagulase-negative staphylococcus) was isolated and infection criteria were not met. Multiple isolates recovered from a single culture site were considered a single infection. Resistance to CHG was determined for isolates recovered from blood cultures using a microtiter dilution method and Bioscreen C reader (MTX Laboratory Systems Inc, Vienna, Virginia).¹⁶

Surveillance for Adverse Skin Reactions

Each patient's skin was examined daily by nursing staff and twice weekly by study personnel. Rashes among patients in the CHG arm were evaluated by study investigators for possible association with CHG bathing and for decisions about whether to exclude the patient from the bathing procedure.

STATISTICAL ANALYSES

We performed an intention-to-treat analysis, that is, patients excluded from the CHG bathing procedure (n=3) were considered as part of the intervention arm. To determine whether there was a difference in primary outcomes or occurrence of primary BSI or clinical sepsis, we calculated the incidence difference (per 1000 patient-days) between the 2 arms and report 95% confidence intervals. We also calculated the incidence difference for central venous catheter-associated primary BSIs per 1000 central line-days (days a patient had a central venous catheter). To evaluate and adjust for potential confounders, we constructed multivariable Poisson and negative binomial regression models. Since parameter estimates were nearly identical from both models and because there was no graphical evidence of overdispersion in BSI counts, we report results from Poisson regression models. We evaluated potential confounders to the association between CHG cleansing and BSI by separately entering all patient-level factors (eg, invasive device use) into multivariate models that retained a term for soap and water bathing and geographic unit. We report the results of a final multivariate model that included the strongest independent predictors of primary BSI. To test the association between geographic unit and patient cleansing method, we included an interaction term. In addition to comparing soap and water with CHG bathing, we evaluated other potential predictors (eg, invasive device use) of primary BSI using Poisson regression.

We graphically compared occurrences of primary BSI or mortality over time between study arms by constructing separate Kaplan-Meier plots; we calculated log-rank test statistics for each curve. For construction of the Kaplan-Meier curve for primary BSI occurrence and calculation of log-rank test statistic, we included only a patient's first BSI. We present the hazard rate for mortality after adjusting for severity of illness (APACHE II score) using Cox proportional hazards models. We calculated antibiotic use for each arm as proportion of days that a patient received an antimicrobial agent and number of new antibiotic prescriptions (ie, >3 days between antibiotic transactions) per 100 patient-days.

We compared patient characteristics between CHG and soap and water arms using the Wilcoxon rank-sum test or the *t* test for continuous variables and χ^2 test for categorical variables. All statistical analyses were done using Stata version 9.2, (Stata-Corp, College Station, Texas).

RESULTS

There were 391 patient admissions (2210 patient-days) in the CHG arm and 445 patient admissions (2119 patient-

Table 1. Patient Characteristics for the Soap and Water and CHG Study Arms as Recorded on Patients' First Day After Admission to the MICU^a

Characteristic	Bathing Method		P Value
	Soap and Water (n=445)	2% CHG (n=391)	
MICU A	204 (46)	220 (56)	.004
WBC count <1000 μ L	9 (2)	16 (4)	.08
Hemodialysis	12 (3)	18 (5)	.14
Feeding tube	175 (39)	172 (44)	.17
Contact isolation	34 (8)	22 (6)	.25
Leukemia or lymphoma	30 (7)	19 (5)	.25
Fecal bag	43 (10)	46 (12)	.33
HIV	33 (7)	36 (9)	.35
Decubitus ulcer	32 (7)	35 (9)	.35
Pressor administered	68 (15)	69 (18)	.36
Diabetes mellitus	71 (16)	70 (18)	.45
Temperature \geq 38.0°C	145 (33)	136 (35)	.50
Arterial line	169 (38)	156 (40)	.57
Indwelling urinary catheter	341 (77)	294 (75)	.63
Mechanical ventilation	156 (35)	140 (36)	.82
Female sex	179 (40)	157 (40)	.98
Central venous catheter	173 (39)	152 (39)	>.99
APACHE II score ^b	21.5 \pm 7	22.4 \pm 7	.07
Age, y	52 \pm 15	53 \pm 16	.51
Pre-MICU length of stay	2.3 \pm 5	2.4 \pm 5	.79

Abbreviations: APACHE II, Acute Physiology and Chronic Health Evaluation II; CHG, chlorhexidine gluconate; HIV, human immunodeficiency virus; MICU, medical intensive care unit; WBC white blood cell.

SI conversion factor: To convert WBC count to $\times 10^9$ /L, multiply by 0.001.

^aData are given as number (percentage) of patients or mean \pm SD value unless otherwise specified.

^bThe APACHE II score was available for 431 patients (97%) in the soap and water arm and 375 patients (96%) in the CHG arm.

days) in the soap and water arm; the differences reflect longer length of stay in the CHG arm (5.7 days vs 4.8 days; *P*=.06). The mean patient age was 52 years, most patients were men, and the 2 groups were similar (**Table 1**). The number and percentage of days a patient had a central venous catheter was higher in the CHG arm (1399 [63%] vs 1248 [59%]). Three subjects were excluded from the CHG arm after developing rashes that were ultimately determined not to be due to CHG.

We identified 31 primary BSIs in 27 patients. Patients in the CHG arm were significantly (61%) less likely to acquire a primary BSI; the incidence of other infections was similar between study arms (**Table 2**). For the combined outcome of primary BSI and culture-negative sepsis, there were less occurrences in the CHG arm, but the difference was not statistically significant (15 vs 11 per 1000 patient-days; *P*=.34). Protection against primary BSI by CHG cleansing was apparent 5 or more days into the MICU stay (**Figure 2**).

Using central line-days as the denominator, we again found that patients in the CHG arm were at lower risk of primary catheter-associated BSI compared with patients bathed with soap and water (6.4 vs 16.8 BSIs per 1000 central line-days; *P*=.01). After adjusting for invasive device use (ie, ventilator-days or urinary bladder catheter-days), the 2 study arms had similar incidences of

Table 2. Comparison of Incidence of Infection by Method of Bathing Patients and Infection Category

Infection Category	Bathing Method				Difference (95% CI)	P Value
	Soap and Water		2% CHG			
	Events	Rate ^a	Events	Rate ^a		
Primary BSI	22	10.4	9	4.1	6.3 (1.2 to 11)	.01
Contaminant	9	4.3	4	1.8	2.4 (-0.9 to 5.7)	.16
Clinical sepsis	9	4.2	16	7.2	-3.0 (-7.5 to 1.5)	.20
Urinary tract infection	17	8.0	13	5.9	2.1 (-2.8 to 7.1)	.41
Ventilator-associated pneumonia	15	6.8	18	7.8	-1.1 (-6.3 to 4.1)	.69
Secondary BSI	5	2.4	5	2.3	0 (-2.8 to 3.0)	.95
<i>Clostridium difficile</i> diarrhea	20	9.4	21	9.5	0 (-5.9 to 5.7)	.98

Abbreviations: BSI, bloodstream infection; CHG, chlorhexidine gluconate; CI, confidence interval.

^aRates are expressed per 1000 patient-days. There were 2119 patient-days in the soap and water arm and 2210 patient-days in the CHG arm.




Figure 2. Kaplan-Meier survival curve for occurrence of bloodstream infection (BSI) by study arm. CHG indicates chlorhexidine gluconate; MICU, medical intensive care unit.

ventilator-associated pneumonia and urinary tract infection (data not shown).

By bivariable analysis, predictors of primary BSI included soap and water bathing; mechanical ventilation; and presence of femoral or internal jugular, but not subclavian, catheters. By multivariable analysis, after adjusting for placement of a femoral central venous catheter, mechanical ventilation, and geographic unit, soap and water bathing remained an independent predictor for occurrence of primary BSI (**Table 3**).

When we analyzed distribution of clinical isolates, we found a significantly higher incidence of urine isolates from patients in the soap and water arm (13 per 1000 patient-days vs 7 per 1000 patient-days; $P = .05$). Although not statistically significant, there was also a higher incidence of isolates from blood cultures in the soap and water arm (24 per 1000 patient-days vs 17 per 1000 patient-days; $P = .11$). Regardless of clinical source, CHG bathing reduced the incidence of gram-positive bacterial isolates; recovery of isolates from other microbial categories (ie, yeasts, molds, and gram-negative bacteria) was similar between study arms. There was a single methicillin-resistant *Staphylococcus aureus* primary BSI, which occurred in the soap and water arm.

We also evaluated in-unit mortality and antimicrobial use. Earlier mortality among patients in the soap and water arm may have been due to chance ($P = .23$). After adjusting for APACHE II score, the earlier mortality was less likely due to chance (hazard ratio, 1.4; 95% confidence interval, 0.9-2.1; $P = .12$) (**Figure 3**). There was a nonsignificant trend toward more new antimicrobial prescriptions per 100 patient-days in the soap and water arm compared with the CHG arm (16 vs 14; $P = .07$); however, the proportion of days patients received antibiotics was similar (0.76 vs 0.79; $P = .37$).

Of 64 blood isolates, 57 (89%) were available for CHG susceptibility testing. The median CHG minimum inhibitory concentration was slightly higher for isolates identified in the CHG arm compared with those in the soap and water arm (2 $\mu\text{g}/\text{mL}$ [interquartile range, 1-4 $\mu\text{g}/\text{mL}$] vs 1 $\mu\text{g}/\text{mL}$ [interquartile range, 0.5-2 $\mu\text{g}/\text{mL}$]; $P = .06$). This was owing to the less frequent recovery of highly CHG-susceptible, gram-positive bacteria in the CHG arm (eg, as shown for primary BSI isolates; **Table 4**) rather than to an increase in the absolute number of isolates with elevated CHG minimum inhibitory concentrations.

COMMENT

In a 12-month clinical trial with a concurrent control group, bathing MICU patients daily with no-rinse, 2% CHG-impregnated cloths resulted in a 61% relative decline in incidence of primary BSIs. This reduction was comparable to or better than reductions in primary BSIs achieved in 3 recent multicenter cohort studies of ICU patients who received bundled evidence-based interventions.^{2,4,5} In contrast to those investigations, we reduced the primary BSI rate by improving a required, routine patient care activity (ie, patient bathing) without introducing additional actions.

Our findings extend the work of others who have reported that skin antiseptics with CHG before device insertion reduces intravascular device-associated infections by reducing bacterial skin burden^{9,10} and that maintaining a low density of bacterial skin colonization at the catheter insertion site through the use of CHG-impregnated dressings while a catheter is in place provides added benefit.¹⁷⁻¹⁹ Compared with soap and water

Table 3. Characteristics Associated With Primary Bloodstream Infection, Determined Using Poisson Regression Models

Characteristic	Patient-Days	Events (Rate) ^a	Incidence Rate Ratio (95% CI) ^b	P Value	Final Multivariate Model	
					Incidence Rate Ratio (95% CI)	P Value
Bathing procedure						
2% CHG	2210	9 (4.1)	1 [Reference]	.02	1.0 [Reference]	
Soap and water	2119	22 (10.4)	2.5 (1.2-5.4)		2.9 (1.4-6.0)	.004
Mechanical ventilation						
No	1185	2 (1.7)	1 [Reference]	.02	1.0 [Reference]	
Yes	3144	29 (9.2)	5.5 (1.3-22)		4.5 (1.2-17.8)	.03
CVC, femoral						
No	2435	9 (3.7)	1 [Reference]	.003	1.0 [Reference]	
Yes	1894	22 (11.6)	3.2 (1.5-6.9)		2.7 (1.3-5.7)	.01
CVC, internal jugular						
No	2827	14 (5.0)	1 [Reference]	.03	NA	NA
Yes	1502	17 (11.3)	2.2 (1.1-4.5)			
CVC, subclavian						
No	3224	20 (6.2)	1 [Reference]	.22	NA	NA
Yes	1105	11 (10.0)	1.7 (0.7-4.0)			
Sex						
Male	2505	22 (8.8)	1 [Reference]	.14	NA	NA
Female	1824	9 (4.9)	0.6 (0.3-1.2)			
MICU						
B	2105	19 (9.0)	1 [Reference]	.16	1 [Reference]	
A	2224	12 (5.4)	0.6 (0.3-1.3)		0.7 (0.3-1.4)	.28

Abbreviations: CHG, chlorhexidine gluconate; CI, confidence interval; CVC, central venous catheter; MICU, medical intensive care unit; NA, not applicable because this variable was not included in the final model.

^aRate per 1000 patient-days.

^bAdjusted for patient care unit (ie, which of the 2 geographically separate MICUs, A or B).




Figure 3. Kaplan-Meier plot of survival by duration of stay in the medical intensive care unit (MICU) for the 2 study arms. APACHE II indicates Acute Physiology and Chronic Health Evaluation II; CHG, chlorhexidine gluconate bathing.

bathing, CHG cleansing results in a persistent several log₁₀ reduction in density of microbial skin colonization.²⁰ Thus, daily bathing with CHG ensures that most patients will have relatively low baseline bacterial skin burden, which would compensate partially for deficiencies in skin antiseptics and minimize inadvertent contamination of the central venous catheter or related equipment during catheter insertion. Further, after the catheter is inserted, the reduced microbial load may decrease risk of contamination of health care workers' hands,¹¹ catheter insertion sites, and catheter hubs. Based on our findings (Figure 2),

Table 4. Microorganisms Isolated in Primary Bloodstream Infections

Microorganism ^a	Bathing Method	
	Soap and Water (n=27)	2% CHG (n=11)
Gram-positive bacteria		
Coagulase-negative staphylococci	15	3
<i>Bacillus</i> species	1	0
<i>Enterococcus</i> species	7	4
<i>Staphylococcus aureus</i>	1	0
Gram-negative bacteria		
<i>Escherichia coli</i>	1	1
<i>Klebsiella pneumoniae</i>	0	1
Yeasts		
<i>Candida albicans</i>	1	0
<i>Candida tropicalis</i>	1	0
<i>Candida krusei</i>	0	2

Abbreviation: CHG, chlorhexidine gluconate.

^aThere were 2 polymicrobial primary bloodstream infections in the CHG arm and 4 in the soap and water arm.

these risks may manifest clinically 5 or more days after MICU admission.

In contrast to the dramatic decline in primary bacteremias in the CHG arm, we detected a nonsignificant increase in the rate of clinical sepsis among patients bathed with CHG-impregnated cloths. This may have resulted from a decreased likelihood of positive blood cultures in syndromes that otherwise would have been categorized

as contaminated blood cultures or primary BSIs. Alternatively, it may have been a function of application of a nonspecific designation (ie, clinical sepsis) to a constellation of signs and symptoms often due to noninfectious causes in critically ill patients.^{21,22}

Compared with the decline in primary bacteremias, the difference in incidence of contaminated blood cultures between the CHG and soap and water arms was of smaller magnitude and may have been due to chance. Alternatively, our sample may not have been large enough to identify a statistically significant reduction. A diminution in blood culture contamination rate is clinically relevant because many patients are treated for infection despite the low likelihood of true BSI; unnecessary treatment exposes patients to antibiotics and may increase the length of stay and costs.²³

We had hypothesized that CHG, in addition to decreasing incidence of primary BSIs, would reduce urinary tract infection rates by lessening periurethral microbial density. Although there was a significant decline in number of urinary isolates in the CHG arm, incidence of urinary infection was unchanged. These findings are consistent with those of previous studies that failed to demonstrate reductions in bacteruria after intensified meatal care.²⁴

We detected a trend toward delayed ICU mortality in the CHG arm; this was not statistically significant, perhaps because we focused on primary BSI for sample size calculations. We did not collect data on 30-day mortality. There was a nonsignificant trend toward fewer antibiotic courses in the CHG arm, although the relative proportion of antibiotic use to treat primary BSIs was not enough to have an impact on total antibiotic consumption.

A frequent concern about increased use of antiseptics is the development of microbial resistance. Blood culture isolates recovered from patients in the CHG arm had slightly higher CHG minimum inhibitory concentrations than did isolates recovered from patients in the soap and water arm. However, this was owing to a reduction in BSI incidence by isolates that typically are inhibited by very low CHG concentrations, such as coagulase-negative staphylococci, rather than by an increase in the number of microorganisms with decreased CHG susceptibility.

Strengths of our study include use of a concurrent control group, crossover design, intention-to-treat analysis, large number of patient-days, and comprehensive capture of infection events by dual manual and electronic surveillance. Our study also has several limitations. The nursing staff could not be blinded to the intervention. Only 1 of 3 physician investigators who categorized BSIs and the category adjudicator were blinded to study arm designation, which could have resulted in bias in classification of primary BSIs. The absence of an increase in secondary BSIs or blood culture contaminants in the CHG arm and the strong agreement between human reviewers and a computer algorithm in the categorization of BSIs argue against misclassification. The CHG arm had fewer patients but equivalent patient-days, which reflected a slightly longer length of stay. Since BSI risk increases during a patient's ICU stay, the longer stay in the CHG arm actually may have biased against finding a protective effect

from CHG cleansing. We performed the study in a single center with a baseline rate of primary BSI higher than rates reported to a national surveillance system²⁵ but lower than those reported during a study in MICUs at other academic centers.⁵ Although our results may not be applicable to all ICUs, the reduced incidence of catheter-associated BSIs in the CHG arm was greater than that observed in all 5 MICUs enrolled in a recent multicenter study of bundled, evidence-based measures to reduce catheter-associated BSI.⁵ Finally, the soap and water arm had a disproportionate number of primary BSIs caused by coagulase-negative staphylococci. Although coagulase-negative staphylococci may be less virulent than some other microbial species, their recovery results in preventable vancomycin use and can be associated with substantial morbidity and mortality.²⁶

Daily cleansing of MICU patients with CHG-impregnated cloths is a simple and effective strategy to decrease the rate of primary BSIs. We believe this approach is a useful adjunctive infection control measure.

Accepted for Publication: July 22, 2007.

Correspondence: Mary K. Hayden, MD, Rush University Medical Center, 1653 W Congress Pkwy, Chicago, IL 60302 (mhayden@rush.edu).

Author Contributions: Dr Bleasdale had full access to all of the data in the study and takes responsibility for the integrity of the data and of the data analysis. *Study concept and design:* Bleasdale, Trick, Hayden, and Weinstein. *Acquisition of data:* Bleasdale, Gonzalez, and Lyles. *Analysis and interpretation of data:* Bleasdale, Trick, Lyles, Hayden, and Weinstein. *Drafting of the manuscript:* Bleasdale, Trick, Gonzalez, and Hayden. *Critical revision of the manuscript for important intellectual content:* Bleasdale, Trick, Lyles, Hayden, and Weinstein. *Statistical analysis:* Trick. *Obtained funding:* Trick and Weinstein. *Administrative, technical, and material support:* Bleasdale, Gonzalez, Lyles, Hayden, and Weinstein. *Study supervision:* Bleasdale, Trick, Lyles, and Weinstein.

Financial Disclosure: None.

Funding/Support: This study was funded by Sage Products Inc and by the Centers for Disease Control and Prevention Cooperative Agreement No. 1 U01 CI000327.

Role of the Sponsor: The funding sources had no role in study design or conduct; data collection, management, interpretation or analysis; or manuscript preparation, review or approval.

Previous Presentation: This study was presented in part at the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 27-30, 2006; San Francisco, California.

Additional Contributions: Alla Aroucheva, PhD (Rush University Medical Center), Catherine Nathan, MS, Anjum Owaisi, MD (Cook County Bureau of Health Sciences), and Thomas Rice, PhD (Rush University Medical Center and Cook County Bureau of Health Sciences) provided assistance with data collection and laboratory work. We thank the patients and staff members of the MICU of John H. Stroger Jr (Cook County) Hospital for study participation.

REFERENCES

1. Eggimann P, Harbarth S, Constantin MN, Touveneau S, Chevrolet JC, Pittet D. Impact of a prevention strategy targeted at vascular-access care on incidence of infections acquired in intensive care. *Lancet*. 2000;355(9218):1864-1868.
2. Centers for Disease Control and Prevention. Reduction in central line-associated bloodstream infections among patients in intensive care units—Pennsylvania, April 2001–March 2005. *MMWR Morb Mortal Wkly Rep*. 2005; 54(40):1013-1016.
3. Berenholtz SM, Pronovost PJ, Lipsett PA, et al. Eliminating catheter-related bloodstream infections in the intensive care unit. *Crit Care Med*. 2004;32(10):2014-2020.
4. Pronovost P, Needham D, Berenholtz S, et al. An intervention to decrease catheter-related bloodstream infections in the ICU. *N Engl J Med*. 2006;355(26):2725-2732.
5. Warren DK, Cosgrove SE, Diekema DJ, et al. A multicenter intervention to prevent catheter-associated bloodstream infections. *Infect Control Hosp Epidemiol*. 2006;27(7):662-669.
6. Safdar N, Maki DG. The pathogenesis of catheter-related bloodstream infection with noncuffed short-term central venous catheters. *Intensive Care Med*. 2004; 30(1):62-67.
7. O'Grady NP, Alexander M, Dellinger EP, et al. Guidelines for the prevention of intravascular catheter-related infections. *Am J Infect Control*. 2002;30(8):476-489.
8. Lio PA, Kaye ET. Topical antibacterial agents. *Infect Dis Clin North Am*. 2004;18 (3):717-733.
9. Maki DG, Ringer M, Alvarado CJ. Prospective randomised trial of povidone-iodine, alcohol, and chlorhexidine for prevention of infection associated with central venous and arterial catheters. *Lancet*. 1991;338(8763):339-343.
10. Garland JS, Buck RK, Maloney P, et al. Comparison of 10% povidone-iodine and 0.5% chlorhexidine gluconate for the prevention of peripheral intravenous catheter colonization in neonates: a prospective trial. *Pediatr Infect Dis J*. 1995; 14(6):510-516.
11. Vernon MO, Hayden MK, Trick WE, Hayes RA, Blom DW, Weinstein RA. Chlorhexidine gluconate to cleanse patients in a medical intensive care unit: the effectiveness of source control to reduce the bioburden of vancomycin-resistant enterococci. *Arch Intern Med*. 2006;166(3):306-312.
12. Bleasdale SCHR, Trick WE, Hayden MK, Blom DW, Vernon MO, Weinstein RA. Does chlorhexidine gluconate (CHG) bathing of medical intensive care unit (MICU) patients prevent blood stream infections (BSIs) [abstract LB2-28]? In: *Final Program of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy*. Washington, DC: American Society for Microbiology Press; 2005:226.
13. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections, 1988. *Am J Infect Control*. 1988;16(3):128-140.
14. Wisniewski MF, Kieszkowski P, Zagorski BM, Trick WE, Sommers M, Weinstein RA. Development of a clinical data warehouse for hospital infection control. *J Am Med Inform Assoc*. 2003;10(5):454-462.
15. Trick WE, Zagorski BM, Tokars JI, et al. Computer algorithms to detect bloodstream infections. *Emerg Infect Dis*. 2004;10(9):1612-1620.
16. Standards NCICL. *Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically*. Wayne, PA: National Committee for Clinical Laboratory Standards; 2003.
17. Garland JS, Alex CP, Mueller CD, et al. A randomized trial comparing povidone-iodine to a chlorhexidine gluconate-impregnated dressing for prevention of central venous catheter infections in neonates. *Pediatrics*. 2001;107(6):1431-1436.
18. Levy I, Katz J, Solter E, et al. Chlorhexidine-impregnated dressing for prevention of colonization of central venous catheters in infants and children: a randomized controlled study. *Pediatr Infect Dis J*. 2005;24(8):676-679.
19. Chambers ST, Sanders J, Patton WN, et al. Reduction of exit-site infections of tunneled intravascular catheters among neutropenic patients by sustained-release chlorhexidine dressings: results from a prospective randomized controlled trial. *J Hosp Infect*. 2005;61(1):53-61.
20. Maki DG. Prospective evaluation of 6 preoperative cutaneous antiseptics regimens for prevention of surgical site infection [abstract 137]. In: *Final Program of the 16th Annual Scientific Meeting of the Society for Healthcare Epidemiology of America*. Alexandria, VA: Society for Healthcare Epidemiology of America; 2006:104.
21. Marik PE. Fever in the ICU. *Chest*. 2000;117(3):855-869.
22. O'Grady NP, Barie PS, Bartlett J, et al; Task Force of the American College of Critical Care Medicine of the Society of Critical Care Medicine in collaboration with the Infectious Disease Society of America. Practice parameters for evaluating new fever in critically ill adult patients. *Crit Care Med*. 1998;26(2): 392-408.
23. Bates DW, Goldman L, Lee TH. Contaminant blood cultures and resource utilization: the true consequences of false-positive results. *JAMA*. 1991;265(3): 365-369.
24. Huth TS, Burke JP, Larsen RA, Classen DC, Stevens LE. Randomized trial of metatal care with silver sulfadiazine cream for the prevention of catheter-associated bacteriuria. *J Infect Dis*. 1992;165(1):14-18.
25. National Nosocomial Infections Surveillance System. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. *Am J Infect Control*. 2004;32(8): 470-485.
26. Lalani T, Kanafani ZA, Chu VH, et al. Prosthetic valve endocarditis due to coagulase-negative staphylococci: findings from the International Collaboration on Endocarditis Merged Database. *Eur J Clin Microbiol Infect Dis*. 2006;25(6): 365-368.